Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Evolocumab公司 医学 动脉粥样硬化性心血管疾病 内科学 疾病 心脏病学 期限(时间) 重症监护医学 胆固醇 载脂蛋白B 物理 量子力学 载脂蛋白A1
作者
Michelle L. O’Donoghue,Robert P. Giugliano,Stephen D. Wiviott,Dan Atar,Anthony Keech,Julia Kuder,Canqing Yu,Sabina A. Murphy,Jose H. Flores‐Arredondo,J. Antonio G. López,Mary Elliott‐Davey,Bei Wang,Maria Laura Monsalvo,Siddique Abbasi,Marc S. Sabatine
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:146 (15): 1109-1119 被引量:247
标识
DOI:10.1161/circulationaha.122.061620
摘要

Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and risk of cardiovascular events and was safe and well tolerated over a median of 2.2 years of follow-up. However, large-scale, long-term data are lacking. Methods: The parent FOURIER trial randomized 27 564 patients with atherosclerotic cardiovascular disease and LDL-C ≥70 mg/dL on statin to evolocumab versus placebo. Patients completing FOURIER at participating sites were eligible to receive evolocumab in 2 open-label extension studies (FOURIER-OLE [FOURIER Open-Label Extension]) in the United States and Europe; primary analyses were pooled across studies. The primary end point was the incidence of adverse events. Lipid values and major adverse cardiovascular events were prospectively collected. Results: A total of 6635 patients were enrolled in FOURIER-OLE (3355 randomized to evolocumab and 3280 to placebo in the parent study). Median follow-up in FOURIER-OLE was 5.0 years; maximum exposure to evolocumab in parent plus FOURIER-OLE was 8.4 years. At 12 weeks in FOURIER-OLE, median LDL-C was 30 mg/dL, and 63.2% of patients achieved LDL-C <40 mg/dL on evolocumab. Incidences of serious adverse events, muscle-related events, new-onset diabetes, hemorrhagic stroke, and neurocognitive events with evolocumab long term did not exceed those for placebo-treated patients during the parent study and did not increase over time. During the FOURIER-OLE follow-up period, patients originally randomized in the parent trial to evolocumab versus placebo had a 15% lower risk of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization (hazard ratio, 0.85 [95% CI, 0.75–0.96]; P =0.008); a 20% lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80 [95% CI, 0.68–0.93]; P =0.003); and a 23% lower risk of cardiovascular death (hazard ratio, 0.77 [95% CI, 0.60–0.99]; P =0.04). Conclusions: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02867813 and NCT03080935.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ccc完成签到,获得积分10
3秒前
萧秋灵完成签到,获得积分10
4秒前
缓慢冥幽完成签到,获得积分10
4秒前
旺仔同学完成签到,获得积分10
13秒前
吉以寒完成签到,获得积分10
19秒前
科研老兵完成签到,获得积分10
21秒前
量子星尘发布了新的文献求助10
24秒前
fys131415完成签到 ,获得积分10
39秒前
执着的忆雪完成签到 ,获得积分10
42秒前
44秒前
闵不悔完成签到,获得积分10
56秒前
阳光火车完成签到 ,获得积分10
57秒前
cc完成签到,获得积分10
1分钟前
合适的寄灵完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
科研通AI5应助cc采纳,获得10
1分钟前
铜泰妍完成签到 ,获得积分10
1分钟前
贝贝完成签到 ,获得积分10
1分钟前
Lrcx完成签到 ,获得积分10
1分钟前
Wen完成签到 ,获得积分10
1分钟前
盘尼西林完成签到 ,获得积分10
1分钟前
LOVE0077完成签到,获得积分10
1分钟前
zhao完成签到,获得积分10
1分钟前
BINBIN完成签到 ,获得积分10
1分钟前
ambrose37完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
fufufu123完成签到 ,获得积分10
1分钟前
开心的大娘完成签到,获得积分10
1分钟前
www完成签到 ,获得积分10
1分钟前
末末完成签到 ,获得积分10
1分钟前
无为完成签到 ,获得积分10
1分钟前
白嫖论文完成签到 ,获得积分10
1分钟前
上官若男应助忧伤的步美采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
2分钟前
从心随缘完成签到 ,获得积分10
2分钟前
花花发布了新的文献求助10
2分钟前
牛奶面包完成签到 ,获得积分10
2分钟前
2分钟前
岁月如歌完成签到 ,获得积分0
2分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022